Regression of Hepatocellular Carcinoma in Vitro and in Vivo by Radiosensitizing Suicide Gene Therapy under the Inducible and Spatial Control of Radiation
- 10 June 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (9) , 1509-1519
- https://doi.org/10.1089/10430349950017842
Abstract
To improve the efficacy and selectivity of gene therapy for hepatocellular carcinoma (HCC), we designed a strategy for suicide gene therapy in conjunction with radiation therapy using an HVJ-liposome vector system. The radio-inducible suicide gene was constructed by insertion of the early growth response gene 1 (Egr-1) promoter upstream of the HSV-tk gene (EGF-tk). First, to test the tumor specificity of Egr-1, RT-PCR and immunohistochemistry were performed. The Egr-1 gene was highly expressed in HCC compared with normal liver, where expression was barely detectable. Next, radiation-inducible activity of the Egr-1 promoter was examined in primary cultured normal hepatocytes and human hepatoma cell lines Huh7, HepG2, and PLC/PRF/5 by luciferase assay as a reporter gene system. Egr-1 promoter activity was markedly increased in hepatoma cell lines in a radiation dose-dependent manner, with maximum activation (15- to 28-fold) 12 hr after irradiation. In contrast, only a twofold increase in activation was noted in normal hepatocytes. An in vitro gene therapy experiment showed that EGR-tk-transduced hepatoma cells became highly sensitive to ganciclovir (GCV) after irradiation, but not without irradiation. GCV with or without irradiation did not show any cytotoxic effects against control gene-transfected cells. In addition, a "radiosensitization effect" was also demonstrated by combination therapy with the HSV-tk/GCV system and irradiation. To examine the efficacy of this EGR-tk/GCV gene therapy in vivo, xenografted liver tumors in nude mice were targeted using the HVJ-liposome vector system. EGR-tk-transfected tumors regressed significantly after a combination therapy of irradiation and GCV in all mice (n = 8), and almost disappeared in 3 weeks without any side effects. In comparison, tumors continued to grow in all mice (n = 8 in each group) treated by transfer of EGR-tk followed by either irradiation without GCV or GCV without irradiation. Our data indicate that HSV-tk gene therapy under the control of a radioinducible promoter is effective, and might be selective for hepatoma cells because of its inducible and radiosensitive capacity after radiation exposure as well as its tumor-specific activation.Keywords
This publication has 35 references indexed in Scilit:
- Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposomeGene Therapy, 1998
- Expression of α-fetoprotein and albumin genes in human hepatocellular carcinomas: Limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapyHepatology, 1998
- Development and Characterization of Cationic Liposomes Conjugated with HVJ (Sendai Virus): Reciprocal Effect of Cationic Lipid forIn VitroandIn VivoGene TransferHuman Gene Therapy, 1997
- Liver-Directed Gene Transfer in Non-Human PrimatesHuman Gene Therapy, 1997
- Induction of the Suicide HSV–TK Gene by Activation of the Egr-1 Promoter with RadioisotopesHuman Gene Therapy, 1997
- Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells.Genes & Development, 1996
- Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase geneHepatology, 1996
- Differential pathways of insulin action upon the hepatitis B surface antigen gene expression and cell proliferation in human hepatoma cellsEndocrinology, 1995
- Phagocyte recognition of cells undergoing apoptosisImmunology Today, 1993
- Hepatocellular carcinomaJournal of Hepatology, 1992